August 2004
Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p1
Trade Publication
Reports on the initiation of the phase IIa clinical trial of DG031, a developmental compound for the prevention of heart attack, deCODE genetics in 2004. Capabilities of the drug; Statement from deCODE CEO Kari Stefanson on the clinical trial; Schedule of the conclusion and presentation of the tests.


Related Articles

  • The failure of antibiotics to prevent heart attacks. Taylor-Robinson, David; Boman, Jens // BMJ: British Medical Journal (International Edition);8/13/2005, Vol. 331 Issue 7513, p361 

    Presents an editorial regarding the failure of antibiotics in the prevention of heart attacks. Discussion of two clinical trials regarding the role of the respiratory pathogen Chlamydia pneumoniae in causing atherosclerotic cardiovascular disease; Description of a trial by Grayston and...

  • Far from the Heart: Receptor cross-talk in remote conditioning. Weber, Christian // Nature Medicine;Jul2010, Vol. 16 Issue 7, p760 

    The article discusses a clinical trial on remote ischemic conditioning that could help in reducing or preventing myocardial infarction. It cites the mechanisms that the researchers used in the study such as occlusion and reperfusion. It elaborates the role of cell as well as morphine and opioid...

  • Omega-3 Fatty Acids Stabilize Atherosclerotic Plaques. Cunningham, Dean S. // Life Extension;Sep2004, Vol. 10 Issue 9, p17 

    Reports that researchers at the University of Southampton in Great Britain have designed a prospective, randomized, double-blind clinical trial to determine the effect of dietary omega-3 fatty acids in patients scheduled to undergo carotid endarterectomy for advanced atherosclerosis. Indication...

  • Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Costa, João; Borges, Margarida; David, Cláudio; Vaz Carneiro, António // BMJ: British Medical Journal (International Edition);5/13/2006, Vol. 332 Issue 7550, p1115 

    Objective To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention. Design Systematic review and meta-analysis. Data sources Cochrane, Medline, Embase, and reference lists up to April 2004. Study...

  • WHAT'S YOUR TEN-YEAR HEART ATTACK RISK?  // Nutrition Action Health Letter;Oct2001, Vol. 28 Issue 8, p6 

    Presents a computational method for estimating one's risk of having a heart attack in ten years time.

  • New ways to foil heart attacks. Faltermayer, Edmund // Time International (South Pacific Edition);3/6/95, Issue 9, p66 

    Emphasizes the importance of recognizing early-warning signs in preventing heart attacks. Inherited vulnerability to heart attacks; Risk factors; Awareness of prodromal symptoms. INSETS: Early signs to watch for.;Great places for heart attacks..

  • Vegetarians reduce risk of heart disease by a third.  // Mayo Clinic Health Letter;June2013, Vol. 31 Issue 6, p4 

    The article reports a research revealing that people who follow a vegetarian diet have 32 percent lower risk of getting a heart attack than people who are non-vegetarians.

  • Drug Lowers Second Heart Attack Risk. Harrar, Sari; Bright, Jennifer // Prevention;Sep2001, Vol. 53 Issue 9, p202 

    Reports that the drug clopidogrel, when added to standard therapy for unstable angina or mild heart attack, cut the risk of a second heart attack, stroke, or vascular death in a study conducted at McMaster University in Hamilton, Ontario.

  • Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction. Scirica, Benjamin M. // Cardiologia Croatica;2012, Vol. 7 Issue 9/10, Special section p1 

    The article presents the clinical trial for vorapaxar for secondary prevention in patients with prior myocardial infarction.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics